Lab
Accurate Mobile Lab Services LLC
Accurate Mobile Lab Services LLC was paid $7.72M by Medicaid between Oct 2022 and Apr 2024, across 9 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 51% of everything it billed.
33Billing provider infoACCURATE MOBILE LAB SERVICES LLC
HICKORY HILLS, IL 60457
HICKORY HILLS, IL 60457
33aNPI1932853918assigned 02/08/2022
33bProvider typeClinical Medical Laboratory
28Total paid$7.72M
24GClaims66,426
24DCodes billed9
24AFirst – last monthOct 2022 – Apr 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#24 of 235
Median peer was paid$123K
This provider vs. median63×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 3,338 | $138K | |
| 2023 | 23,778 | $1.14M | |
| 2024incomplete | 39,310 | $6.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 51% | 16,157 | 12,822 | $3.94M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 21% | 13,206 | 12,472 | $1.59M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 11% | 6,301 | 1,693 | $846K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.0% | 8,254 | 2,167 | $615K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.6% | 7,141 | 1,937 | $357K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.5% | 8,252 | 2,167 | $192K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.2% | 6,874 | 2,167 | $170K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 191 | 137 | $8K |
| 87913 | <1% | 50 | 49 | $6K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialABU REALH, MOHAMMED (MEMBER MANAGER)